These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 33149595)

  • 21. A Critical Review of the Efficacy and Safety of Inclisiran.
    Hardy J; Niman S; Pereira E; Lewis T; Reid J; Choksi R; Goldfaden RF
    Am J Cardiovasc Drugs; 2021 Nov; 21(6):629-642. PubMed ID: 33954930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran.
    Elserafy AS; Bendary A; Elbahry A; Farag E; Mostafa T; Sanad O; Elkersh A; Selim M; Ragy H; Khamis H; Abdo W; Reda A
    Cardiol Ther; 2022 Dec; 11(4):461-471. PubMed ID: 36053454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inclisiran - a new era in lipid-lowering therapy].
    Voevoda MI; Gurevich VS; Ezhov MV; Sergienko IV
    Kardiologiia; 2022 Jun; 62(6):57-62. PubMed ID: 35834343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.
    Banerjee Y; Pantea Stoian A; Cicero AFG; Fogacci F; Nikolic D; Sachinidis A; Rizvi AA; Janez A; Rizzo M
    Expert Opin Drug Saf; 2022 Jan; 21(1):9-20. PubMed ID: 34596005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
    Nozue T
    J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries.
    Nishikido T; Ray KK
    Front Cardiovasc Med; 2018; 5():199. PubMed ID: 30761308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy.
    Kosmas CE; DeJesus E; Morcelo R; Garcia F; Montan PD; Guzman E
    Drugs Context; 2017; 6():212511. PubMed ID: 29209403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review.
    Merćep I; Friščić N; Strikić D; Reiner Ž
    Cardiovasc Ther; 2022; 2022():8129513. PubMed ID: 35237348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and Safety of Inclisiran, A Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9.
    Chandra Ghosh G; Bandyopadhyay D; Ghosh RK; Mondal S; Herzog E
    Am J Cardiol; 2018 Oct; 122(7):1272-1277. PubMed ID: 30075894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.
    Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK
    Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Keep recycling going: New approaches to reduce LDL-C.
    Klein-Szanto AJP; Bassi DE
    Biochem Pharmacol; 2019 Jun; 164():336-341. PubMed ID: 30953636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PCSK9 inhibitors: A new era of lipid lowering therapy.
    Chaudhary R; Garg J; Shah N; Sumner A
    World J Cardiol; 2017 Feb; 9(2):76-91. PubMed ID: 28289523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia.
    Robinson JG
    Prog Cardiovasc Dis; 2016; 59(2):165-171. PubMed ID: 27498088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
    Pirillo A; Catapano AL
    Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RNA Silencing in the Management of Dyslipidemias.
    Henney NC; Banach M; Penson PE
    Curr Atheroscler Rep; 2021 Sep; 23(11):69. PubMed ID: 34468873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.